Verastem data on ovarian cancer drug combo set for IGCS 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. MRK
7. LVS
8. SAP
9. CSX
10. LRCX

Go back to Verastem data on ovarian cancer drug combo set for IGCS 2026

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

September 24, 2026 8:30 AM EDT

Oral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patients

New external control arm analysis of avutometinib plus defactinib versus standard-of-care treatment for LGSOC will be presented during Poster Rounds

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that an abstract about molecular profiling and tumor biomarker analysis from the Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib... More